ARDENT HEALTH PARTNERS ($ARDT) posted quarterly earnings results for Q4 2025 on Wednesday, March 4th. The company reported earnings of $0.32 per share, missing estimates of $0.35 by $0.03. The company also reported revenue of $1,605,080,000, missing estimates of $1,663,799,428 by $-58,719,428.
Stock price change since market close: -11.31%
You can see Quiver Quantitative's $ARDT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARDENT HEALTH PARTNERS Hedge Fund Activity
We have seen 69 institutional investors add shares of ARDENT HEALTH PARTNERS stock to their portfolio, and 89 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GOLDENTREE ASSET MANAGEMENT LP added 1,150,000 shares (+99.7%) to their portfolio in Q4 2025, for an estimated $10,154,500
- ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC removed 781,556 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,901,139
- AMERIPRISE FINANCIAL INC removed 647,778 shares (-36.6%) from their portfolio in Q4 2025, for an estimated $5,719,879
- MILLENNIUM MANAGEMENT LLC removed 642,170 shares (-50.6%) from their portfolio in Q4 2025, for an estimated $5,670,361
- PIER CAPITAL, LLC removed 580,620 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,126,874
- CASTLEKNIGHT MANAGEMENT LP removed 570,969 shares (-32.8%) from their portfolio in Q4 2025, for an estimated $5,041,656
- BRIDGEWAY CAPITAL MANAGEMENT, LLC added 491,961 shares (+108.2%) to their portfolio in Q4 2025, for an estimated $4,344,015
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARDENT HEALTH PARTNERS Analyst Ratings
Wall Street analysts have issued reports on $ARDT in the last several months. We have seen 6 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 12/18/2025
- Guggenheim issued a "Buy" rating on 11/18/2025
- Mizuho issued a "Outperform" rating on 11/18/2025
- Truist Securities issued a "Buy" rating on 11/14/2025
- Stephens & Co. issued a "Overweight" rating on 11/14/2025
- RBC Capital issued a "Outperform" rating on 11/14/2025
- B of A Securities issued a "Underperform" rating on 11/13/2025
To track analyst ratings and price targets for ARDENT HEALTH PARTNERS, check out Quiver Quantitative's $ARDT forecast page.
ARDENT HEALTH PARTNERS Price Targets
Multiple analysts have issued price targets for $ARDT recently. We have seen 10 analysts offer price targets for $ARDT in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Benjamin Rossi from JP Morgan set a target price of $11.0 on 01/20/2026
- Ann Hynes from Mizuho set a target price of $12.0 on 12/18/2025
- A.J. Rice from UBS set a target price of $14.0 on 12/18/2025
- Jason Cassorla from Guggenheim set a target price of $15.0 on 11/18/2025
- Ben Hendrix from RBC Capital set a target price of $16.0 on 11/14/2025
- Craig Hettenbach from Morgan Stanley set a target price of $12.0 on 11/14/2025
- David Macdonald from Truist Securities set a target price of $13.0 on 11/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
